Portfolio Choice  123    15   

Published: Jun 15, 2022
Updated: Jun 15, 2022

TORRENT PHARMACEUTICALS
BSE ticker code 500420
NSE ticker code TORNTPHARM
Major activity Pharmaceuticals
Managing Director Samir Mehta
Equity capital Rs. 84.62 crore; FV Rs. 05
52 week high/low Rs. 3305 / Rs. 2485
CMP Rs. 2890.00
Market Capitalisation Rs. 48905.37 crore
Recommendation Accumulate at declines
Pole player in domestic branded medicines

Torrent Pharmaceuticals is one of the country’s leading pharmaceutical companies, being the eighth largest in India. It ranks among the top 5 players in the country in cardiac, central nervous system (CNS), vitamins, minerals and nutrients (VMN) and gastro-intestinal therapeutic areas. Despite the pandemic, its financial performance is quite remarkable. What is more, its future prospects are all the more promising

Consider:

  • The company stands in a strong position in the country’s pharmaceutical industry. It has 10 brands above Rs 100 crore. Its domestic business franchise has chronic and subchronic therapeutic segments which contribute around 73 per cent of the India business and which have an operating margin of more than 30 per cent. The company has 70 brands which are leaders in their respective markets. The largest therapy is cardiac, which contributes 31 per cent of domestic revenues, followed by GI, CNS and vitamins at 16% and 15% respectively. The management gives a lot of emphasis on research and development, with R&D spend accounting for around 5 to 7 per cent of sales.
  • The company is doing quite well on the export front. Today it has a presence in 40 countries and derives almost 55 per cent of its revenues from exports, mainly from the US, Europe, Brazil and the Philippines. The company was facing regulatory challenges and its revenue growth was under stress on account of compliance issues of the Dahej and Indrad facilities with the US FDA. As the company has already submitted CAPA (corrective and preventive action), the problem has been sorted out and the company’s business in the US is on the rise. Meanwhile, the company’s European business is mainly in Germany and the UK where it has a direct presence. Germany – the largest market in western Europe — is the 4th largest global market in the world. Torrent is the number one player among Indian companies in the German market. Of late, the German business contributes around 12 to 13 per cent of Torrent’s total revenues. As a strategic move, Torrent acquired Heumann Pharma GmbS and Co in 2005.
  • Another promising country for Torrent is Brazil, where Torrent is the largest Indian company and contributes around 9 per cent of total sales. Torrent has nine pending filings with ANVISA and has a development basket of around 20 products. Prospects for the company are highly encouraging in Germany and Brazil. Torrent plans to gain marketshare through introducing speciality focus, enhancing field force productivity and introducing new products. Currently, the company has commercialized 23 branded generics and 20 generic products. In its branded generic portfolio, the company has 9 filings under approval, 23 under preparation for filing in existing business and 19 in new business. The company expects 3 to 4 products launches per year from its own portfolio. Licensing opportunities would provide further growth opportunities in Brazil.
  • The company has expanded its business operations through the inorganic route. In 2014, it acquired the branded formulation business of Elder Pharma in India and Nepal for Rs 2,000 crore. As a result, about 30 brands were added to Torrent’s portfolio, which included popular brands like Shelcal, Chymural, and Carnisure. Three years later in 2017, the company acquired the branded business of Unichem Laboratories for India and Nepal at a cost of around Rs 3,000 crore. Both these acquisitions gave a big boost to the topline as well as bottomline of Torrent.
  • The company is successfully deleveraging its balance sheet by bringing down the debt burden. Needless to say, the interest burden, as a result, was reduced from Rs 481 crore in fiscal 2019 to Rs 236 crore in fiscal 2022, and this is expected to go down further.

The company’s share price is currently quoted around Rs 617 and is sure to give good returns to investors in due course.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2018-19 7672.80 683.10 40.40 340.0 299.80 14.60
2019-20 7939.30 999.50 59.10 640.0 285.00 20.90
2020-21 8004.80 1239.10 73.20 700.0 344.90 23.30
2021-22 8508.00 1084.38 64.10 960.0 351.80 23.25
BCL INDUSTRIES AND INFRASTRUCTURE
BSE ticker code 524332
NSE ticker code BCLIND
Major activity Edible Oils
Chairman R.C. Nayyar
Equity capital Rs. 24.15 crore; FV Rs. 10
52 week high/low Rs. 525 / Rs. 183
CMP Rs. 372.05
Market Capitalisation Rs. 898.50 crore
Recommendation Buy at declines
Sales triple in last five years

BCL Industries and Infrastructure Ltd, a Mittal group company, is one of the largest agro-based companies in North India. This vertically integrated company is engaged in the manufacture of edible oils, including soyabean oil, sunflower oil, cottonseed oil and rice bran oil, under the brand name ‘Homecook’. It also manufactures Vanaspati under the brand name ‘Do Khajoor’

BCL is also engaged in the grain-based distillery business. In fact, it is the only company, not only in India but also in the entire south Asian region, that has a forward and backward integrated distillery-ethanol plant. The company has a unique expertise in producing ENA ethanol from multiple crops. It is going from strength to strength and its future prospects are all the more exciting.

Consider:

  • The company has been in expansion mode ever since its inception in 1976 when it was incorporated as Bhatinda Chemicals Ltd. In 1991-92, it set up a new solvent extraction plant of 150/200 tpd capacity and a Vanaspati plant of 25 tpd. After a year, it increased the production capacity to 15,000 tpd. In 2001-2002, this capacity was doubled to 30,000 tpd. As ‘Do Khajoor’ became more and more popular, the company’s topline as well as bottomline started going up.
  • BCL has developed expertise in producing ENA ethanol from multiple crops. This allows it to reduce dependency on a single crop and avoid the vagaries of raw material price fluctuations. The company has already set up a plant at Bhatinda of 200 klpd capacity and is now setting up another plant nearby with the same capacity. At the same time, its subsidiary, Savak Sha Distillery, has also set up an ethanol plant with a capacity of 200 klpd. The plant has been set up with the help of internal accruals and without raising any debt. The subsidiary has also got an approval to set up another ethanol plant with a capacity of 100 klpd at the same premises. This plant is being set up at minimal capex due to the existing facilities. With this 100 klpd plant going into production by the end of fiscal 2023, the company’s total ethanol capacity will go up to 700 klpd – taking into account the 400 klpd capacity of the main plant and the 300 klpd capacity of the subsidiary. This will make BCL one of the largest producers of ethanol from grains in the private sector in India
  • The company has emerged as one of the leading manufacturers of high-quality rice bran oil in the world. In 2007-08, it set up a deodorizing system to achieve an excellent quality of rice bran refined oil. Little wonder that the company received the BK Goenka SEA award for refined rice bran oil twice!
  • Needless to say, the growing business of the company is well reflected in its financial growth. During the last six years, its sales turnover has expanded from Rs 642 crore in fiscal 2017 to Rs 1,988 crore in fiscal 2022, with operating profit advancing from Rs 37 crore to Rs 138 crore and the profit at net level inching up from Rs 10 crore to Rs 85 crore during this period. BCL’s financial position has been getting stronger and stronger by the day, with reserves at the end of March 2022 standing at Rs 261 crore against an equity capital of Rs 27 crore, that too after a 1:1 bonus issue in 1992. The company has been regularly paying dividends, the rate for the last year being 50 per cent.

Prospects for the company going ahead are all the more promising and this will be a very good addition to the portfolios of longterm investors.

CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2018-19 890.50 41.30 21.60 12.0 107.70 26.30
2019-20 918.32 26.00 13.59 -- 112.40 29.80
2020-21 1427.20 41.80 17.30 50.0 117.70 16.70
2021-22 1987.74 84.84 35.10 50.0 151.60 16.68
VISAKA INDUSTRIES
BSE ticker code 509055
NSE ticker code VISAKAIND
Major activity Cement & Cement Products
Managing Director Dr. G. Vivekanand
Equity capital Rs. 17.28 ; FV Rs. 10
52 week high/low Rs. 874 / Rs. 490
CMP Rs. 516.25
Market Capitalisation Rs. 892.13 crore
Recommendation Buy at declines
At forefront of building products

The second largest cement asbestos product manufacturer in India, Visaka Industries has multiple products — from cement sheets and fibre cement boards to hybrid solar roofs and fibre yarn. Since its inception in 1981, the company has remained at the forefront, developing sustainable products and meeting demands from domestic as well as international markets. The company has been growing steadily and its future prospects seem to be all the more promising.

Consider:

  • The Hyderabad-based company employs a unique business model for its product segment. Its asbestos cement sheet (ACS) finds extensive usage in urban and semi-urban interiors while cement asbestos products like V-boards and panels largely address rural markets, allowing for adequate geographic de-risking. The company’s customers for V-panels and boards include the GMR group, Shapoorji Pallonji, Soma Enterprises, TCS, Gujarat Ambuja, the Eanadu group, Uranium Corporation of India and Larsen&Toubro. Its building products are marketed directly to retailers, eliminating the conventional company-distributor-retailer model and resulting in a better marketplace understanding. As a result, the company enjoys an enduring relationship with an extensive network of agents and retailers.
  • Visaka has emerged as a credible, passionate and innovative solution provider. With its transformed product portfolio under V-next, the company enables contractors, builders, architects and applicators to emphasise sustainable architecture and build the future. The company’s V-next boards are designed to provide strength and stability as well as aesthetic solutions. V-next premium planks, a speciality grade product from Visaka, have become the choice of many consultants, engineers, builders and contractors and have been tested to survive even in extreme outdoor applications. In short, demand for the company’s products is constantly on the rise.
  • The company also manufactures and is a global supplier of the wonder yarn – a human-made spool for various fabric applications across garments, apparels, furnishings, automotive fabrics and other technical textiles. The company is famed for roofing the largest Muratec Twin jet spun yarn technology facility with its world-class manufacturing set-up.
  • With a view to addressing energy demands sustainability, the company has launched a path-breaking hybrid rooftop solar product called ATUM – the first of its kind in India. With its superior technological capabilities, ATUM is thermally efficient and generates 20% more revenue when compared to conventional solar panels. ATUM is the only renewable energy solution that is both a roof and solar panel designed to meet consistent energy demands that one can manage on his/her smartphone.
  • With 12 manufacturing facilities, 13 marketing offices and a pan-India distribution channel of over 7,000 dealer outlets, Visaka has emerged as a sustainable business enterprise and a Green Pro Certified Organisation. Its excellent corporate governance and professional management have kept Visaka on a steady growth path.
  • All these factors have quickened the pace of growth of the company on the financial front. During the last six years, the company’s sales turnover has expanded from Rs 967 crore in fiscal 2017 to Rs 1,416 crore, with the profit at net level taking a high jump from Rs 44.45 crore to Rs 118.53 crore during this period. The company’s financial position is very strong, with reserves at the end of March 2022 standing at Rs 715 crore – over 41 times its equity capital of Rs 17.28 crore. The company is deleveraging its balance sheet by reducing debt. The interest burden as a result has gone down from Rs 20 crore in fiscal 2019 to Rs 11.56 crore in fiscal 2022. and in the very near future Visaka will be a totally debtfree company.

This is a stock worth investing in, and discerning investors should include it in their portfolios.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Series Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2018-19 1136.40 67.60 42.60 70.0 314.50 14.30
2019-20 1050.40 49.10 30.90 150.0 318.00 9.80
2020-21 1146.50 110.60 67.10 150.0 377.40 19.60
2021-22 1415.81 118.09 68.30 150.0 423.60 17.44

February 15, 2025 - First Issue

Industry Review

VOL XVI - 10
February 01-15, 2025

Formerly Fortune India Managing Editor Deven Malkan Assistant Editor A.K. Batha President Bhupendra Shah Circulation Executive Warren Sequeira Art Director Prakash S. Acharekar Graphic Designer Madhukar Thakur Investment Analysis CI Research Bureau Anvicon Research DD Research Bureau Manager (Special Projects) Bhagwan Bhosale Editorial Associates New Delhi Ranjana Arora Bureau Chief Kolkata Anirbahn Chawdhory Gujarat Pranav Brahmbhatt Bureau Cheif Mobile: 098251-49108 Bangalore Jaya Padmanabhan Bureau Chief Chennai S Gururajan Bureau Chief (Tamil Nadu) Ludhiana Ajitkumar Vijh Bhubaneshwar Braja Bandhu Behera

Want to Subscribe?


Lighter Vein

Popular Stories

E-Waste Dilemma Tackling E-Waste Via Reverse Logistics, By Vihaan Shah

A modern-day enigma and a ramification of humanity's never-ending advancements, e-waste refers to the scum con- cealed by the outward glow of ever-advancing technology.

Archives

About Us    Contact Us    Careers    Terms & Condition    Privacy Policy

Liability clause: The investment recommendations made here are based on the personal judgement of the authors concerned. We do not accept liability for any losses that might occur. All rights reserved. Reproduction in any manner, in whole or in part, in English or in any other language is prohibited.

Copyright © 1983-2025 Corporate India. All Rights Reserved.

www.corporateind.com | Cookie Policy | Disclaimer